Turbine

Turbine

Private
London, EnglandHealthcare & Life Scienceshttps://www.turbine.ai

Last Round

Series B

Feb 24, 2026

Total Funding Raised

$71.22M

Momentum Score

50 /100

Company Overview

Turbine (Drug Discovery) is a biotechnology company that develops cancer combination therapies aimed at elucidating disease biology and creating personalized treatment plans through advanced bioinformatics and artificial intelligence.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Subscription SaaS

AI Layer

Infrastructure

Keywords

AI drug discoverycell simulationoncology drug discoverybiological simulationcancer digital twinin-silico drug discoverybiotech AItarget discoverypreclinical drug discoverybiomarker discoveryvirtual lab platformbiopharma partnershipsinterpretable AIwet lab validationADC discoverycombination therapy design

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Turbine Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Turbine Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BFeb 24, 2026
Series AApr 4, 2025
Series A ExtensionMay 16, 2024
Series AJun 20, 2023
Series ANov 22, 2022
Seed
Jan 7, 2021

Key People

Founding team and executive leadership

Daniel Veres

Chief Scientific Officer, Co-Founder

Founding Team

Kristóf Szalay

CTO & Founder

Founding Team

Szabolcs Nagy

CEO, Co-founder

Founding Team

Turbine Investors

Notable investors and investment history

InvestorRounds
B Capital GroupSeries A
Interactive Venture PartnersSeries B
Day One CapitalSeries A
o2h venturesSeries A, Seed
Merck Global Health Innovation FundSeries B, Series A
Accenture VenturesSeries A Extension
Fin Venture CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 4, 2025

    Will simulate hard-to-treat cancer patient populations.

  • Jul 10, 2025

    Gregory Vladimer appointed to Scientific Advisory Board.

Turbine Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Turbine Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Turbine's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon, England
Employee Range105
Year Founded2016
Last FundingFeb 24, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.